RFA-HL-24-012: Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $300,000 to small businesses. Applications closed on September 6, 2023.
From the official notice on Grants.gov, last changed September 6, 2023. Checked November 7, 2026.
- Award ceiling$300,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-24-012 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-HL-24-015 | September 6, 2023 | Closed October 27, 2023 | Closed |
Key dates
| Posted | July 14, 2023 |
|---|---|
| Deadline | September 6, 2023 |
| Archived by Grants.gov | October 6, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following:See full Notice of Funding Opportunity for additional information on eligibility.
Is this a realistic fit?
- Past Lung Diseases Research awards averaged $1.7 million; this notice allows up to $300,000 per award.
- Most of the program's money (59% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The objective of the Molecular Atlas of Lung Development (LungMAP) program is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. LungMAP is an open access resource integrating multi-scale, high-content, high-resolution information to define lung cells with gene expression, physiological states, 3-dimensional locations, as well as developmental and pathological trajectories.
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-24-012 still open?
No. It closed on September 6, 2023.
Who can apply for Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)?
Closed September 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each.
Who has won Lung Diseases Research grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, New England Research Institutes Inc, The Trustees of the University of Pennsylvania. The program made 5 awards worth $8.7 million in that time.
Similar open grants
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)
- Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)